STOCK TITAN

Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Beam Therapeutics Inc. has a significant shareholder group led by Farallon Capital Management, L.L.C. and affiliated investment funds and individuals (together, the Reporting Persons). They collectively report beneficial ownership of 10,282,210 Shares of Beam’s common stock, representing 9.99% of the outstanding class as of the reporting date.

The Farallon funds directly hold 10,236,396 Shares and 1,404,988 Common Stock Purchase Warrants. Because the warrants are subject to a 9.99% Beneficial Ownership Limitation, only 45,814 Shares underlying the warrants are currently counted as beneficially owned, with the remaining 1,359,174 warrants treated as not exercisable within 60 days. The Farallon funds are entitled to receive dividends and sale proceeds from these securities.

Positive

  • None.

Negative

  • None.
Beneficially owned Shares 10,282,210 Shares Aggregate Beam common stock beneficially owned by the Reporting Persons as of the reporting date
Percent of class 9.99% Percentage of Beam’s outstanding common stock beneficially owned under Section 13(d)
Shares held directly 10,236,396 Shares Beam common stock directly held by the Farallon Funds
Total warrants held 1,404,988 warrants Common Stock Purchase Warrants held by the Farallon Funds, each for one Share
Exercisable under cap 45,814 Shares Shares underlying warrants currently exercisable within 60 days under the 9.99% Beneficial Ownership Limitation
Non-counted warrants 1,359,174 warrants Remaining warrants treated as not exercisable within 60 days for beneficial ownership
Beneficial Ownership Limitation regulatory
"The terms of the Warrants provide that Warrants may not be exercised to the extent that, after giving effect"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Common Stock Purchase Warrants financial
"As of the date requiring the filing, the Farallon Funds hold an aggregate of 1,404,988 Common Stock Purchase Warrants"
Common stock purchase warrants are tradable instruments that give the holder the right to buy a company’s common shares at a set price before a specified date, like a coupon that lets you purchase stock later at a fixed rate. They matter to investors because they offer a way to gain future upside if the stock rises, but when exercised they increase the number of shares outstanding and can reduce existing shareholders’ ownership and earnings per share.
beneficially owned regulatory
"Accordingly, in providing the beneficial ownership information set forth herein, the Reporting Persons have assumed"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Schedule 13G regulatory
"Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
investment manager financial
"Farallon Capital Management, L.L.C., a Delaware limited liability company, which is the investment manager"

FAQ

How much of Beam Therapeutics (BEAM) does Farallon currently beneficially own?

Farallon and its affiliates report beneficial ownership of 10,282,210 Shares of Beam Therapeutics common stock, representing 9.99% of the outstanding Shares, based on Section 13(d) calculations and warrant exercise limits described in the filing.

How many Beam Therapeutics (BEAM) shares and warrants do the Farallon funds hold?

The Farallon funds directly hold 10,236,396 Shares of Beam common stock and 1,404,988 Common Stock Purchase Warrants. Each warrant is exercisable for one Share, subject to a 9.99% Beneficial Ownership Limitation on total holdings.

What is the 9.99% Beneficial Ownership Limitation in the Beam (BEAM) Farallon filing?

The warrants held by Farallon may not be exercised if doing so would cause beneficial ownership to exceed 9.99% of Beam’s outstanding Shares. This constraint limits how many warrants can be counted as currently exercisable for reporting purposes.

How many Beam (BEAM) shares underlying Farallon’s warrants are counted as beneficially owned?

Due to the 9.99% Beneficial Ownership Limitation, only 45,814 Shares underlying Farallon’s 1,404,988 warrants are treated as currently exercisable and beneficially owned; the remaining 1,359,174 warrants are excluded from 60-day ownership calculations.

Who receives dividends and sale proceeds from Farallon’s Beam (BEAM) holdings?

The filing states that the Farallon Funds have the right to receive dividends from, and the proceeds from the sale of, the Beam securities beneficially owned by the Reporting Persons, reflecting their economic interest in the position.

Which entities make up the Farallon funds holding Beam Therapeutics (BEAM)?

The position is held across multiple funds, including Farallon Capital Partners, L.P., several Farallon Capital Institutional Partners funds, Four Crossings Institutional Partners V, and Cayman-based vehicles such as FCOI II, F5 Master I, and Farallon Healthcare Partners Master.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





07373V105

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/13/2026
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/13/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/13/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/13/2026
Farallon Healthcare Partners Master, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/13/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/13/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/13/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/13/2026
Farallon Healthcare Partners (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/13/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/13/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/13/2026

Comments accompanying signature: Each of Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C, and Farallon Healthcare Partners (GP), L.L.C. has executed this statement in Mill Valley, California, on behalf of itself and each fund for which it is the general partner.
Exhibit Information

Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k)